FORTRESS BIOTECH ANNOUNCES CELLVATION’S CEVA101 GRANTED FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY
DATA FROM CLINICAL STUDY OF CELL THERAPY FOR TREATMENT OF TRAUMATIC BRAIN INJURY
FORTRESS BIOTECH FORMS NEW SUBSIDIARY, CELLVATION, INC., TO DEVELOP NOVEL THERAPIES FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY
